» Articles » PMID: 32634498

Blood Carbon Dioxide Tension and Risk in Pulmonary Arterial Hypertension

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2020 Jul 8
PMID 32634498
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Low partial pressure of blood carbon dioxide (PCO) is common in patients with pulmonary arterial hypertension (PAH) and may inform on clinical outcomes. We investigated whether PCO measurements could provide prognostic information in addition to standard risk assessment in this group of patients.

Methods: We conducted a retrospective observational cohort study on patients with newly diagnosed idiopathic, heritable or drug/toxin-induced PAH recruited from two European centres. Arterialised capillary blood gas analyses at diagnosis and follow-up were incorporated into standard risk assessment strategies and related to outcomes, defined as lung transplant or death. C statistics from receiver-operated characteristics and Cox regression models were used to assess the predictive value of models with and without PCO measurements. Unsupervised clustering was applied to assess the relation of PCO to haemodynamic and pulmonary function variables.

Results: Low PCO measured at diagnosis and follow-up was significantly associated with inferior outcomes in 204 patients with PAH. PCO provided prognostic information independent of established non-invasive variables. Integrating PCO in risk strata improved C statistics of non-invasive and mixed invasive/non-invasive models, and revealed more accurate outcome estimates in regression models. Pairwise correlation and unsupervised cluster analyses supported a link between PCO and haemodynamic variables, particularly with cardiac output, in PAH.

Conclusions: Measuring PCO at diagnosis and during follow-up in patients with PAH provided independent prognostic information and has the potential to improve current risk assessment strategies.

Citing Articles

Pulmonary hypertension in adults with congenital heart defects (ACHDs)-in light of the 2022 ESC PAH guidelines-part I: definition, epidemiology, classification, diagnostics, genetics, risk stratification and follow-up, gender aspects.

Kaemmerer H, Diller G, Dahnert I, Achenbach S, Eichstaedt C, Eicken A Cardiovasc Diagn Ther. 2024; 14(5):935-948.

PMID: 39513141 PMC: 11538847. DOI: 10.21037/cdt-24-148.


Definition, classification and diagnosis of pulmonary hypertension.

Kovacs G, Bartolome S, Denton C, Gatzoulis M, Gu S, Khanna D Eur Respir J. 2024; 64(4).

PMID: 39209475 PMC: 11533989. DOI: 10.1183/13993003.01324-2024.


Risk stratification and treatment goals in pulmonary arterial hypertension.

Dardi F, Boucly A, Benza R, Frantz R, Mercurio V, Olschewski H Eur Respir J. 2024; 64(4).

PMID: 39209472 PMC: 11525341. DOI: 10.1183/13993003.01323-2024.


Prognostic Value of Serial Risk Stratification in Adult and Pediatric Pulmonary Arterial Hypertension: A Systematic Review.

Lokhorst C, van der Werf S, Berger R, Douwes J J Am Heart Assoc. 2024; 13(13):e034151.

PMID: 38904230 PMC: 11255703. DOI: 10.1161/JAHA.123.034151.


Significance of Hypocapnia in the Risk Assessment of Patients with Pulmonary Hypertension.

Aetou M, Wahab L, Dreher M, Daher A J Clin Med. 2023; 12(19).

PMID: 37834951 PMC: 10573368. DOI: 10.3390/jcm12196307.